[go: up one dir, main page]

DK0773226T3 - Propiophenonderivater og fremgangsmåder til fremstilling deraf - Google Patents

Propiophenonderivater og fremgangsmåder til fremstilling deraf

Info

Publication number
DK0773226T3
DK0773226T3 DK96117088T DK96117088T DK0773226T3 DK 0773226 T3 DK0773226 T3 DK 0773226T3 DK 96117088 T DK96117088 T DK 96117088T DK 96117088 T DK96117088 T DK 96117088T DK 0773226 T3 DK0773226 T3 DK 0773226T3
Authority
DK
Denmark
Prior art keywords
processes
preparation
propiophenone derivatives
hydrogen atom
propiophenone
Prior art date
Application number
DK96117088T
Other languages
English (en)
Inventor
Kenji Tsujihara
Kunio Saito
Mitsuya Hongu
Mamoru Matsumoto
Kozo Oka
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of DK0773226T3 publication Critical patent/DK0773226T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK96117088T 1995-11-07 1996-10-24 Propiophenonderivater og fremgangsmåder til fremstilling deraf DK0773226T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7288487A JP3059088B2 (ja) 1995-11-07 1995-11-07 プロピオフェノン誘導体およびその製法

Publications (1)

Publication Number Publication Date
DK0773226T3 true DK0773226T3 (da) 1999-08-30

Family

ID=17730854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96117088T DK0773226T3 (da) 1995-11-07 1996-10-24 Propiophenonderivater og fremgangsmåder til fremstilling deraf

Country Status (12)

Country Link
US (1) US5767094A (da)
EP (1) EP0773226B1 (da)
JP (1) JP3059088B2 (da)
KR (1) KR100333572B1 (da)
CN (1) CN1049222C (da)
AT (1) ATE175676T1 (da)
CA (1) CA2189603C (da)
DE (1) DE69601345T2 (da)
DK (1) DK0773226T3 (da)
ES (1) ES2128137T3 (da)
SG (1) SG40895A1 (da)
TW (1) TW460477B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0850948B1 (en) * 1996-12-26 2002-04-24 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
WO2001015706A1 (en) 1999-08-27 2001-03-08 Ehrenkranz Joel R L Method of using dihydrochalcone derivatives to block glucose transfer
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2442917C (en) * 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
EP1392326B1 (en) * 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
JP4130466B2 (ja) * 2003-08-01 2008-08-06 田辺三菱製薬株式会社 新規化合物
TW200521131A (en) * 2003-08-01 2005-07-01 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
US7094764B2 (en) * 2003-08-01 2006-08-22 Janssen Pharmaceutica N.V. Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US7129220B2 (en) * 2003-08-01 2006-10-31 Janssen Pharmaceutica N.V Substituted indole-O-glucosides
RS20060320A (en) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
FR2862303B1 (fr) * 2003-11-17 2006-01-06 Agronomique Inst Nat Rech Preparations colorantes hydrosolubles jaunes derivees des dihydrochalcones, leur procede des preparation, et leurs utilisations
TWI332707B (en) 2005-08-04 2010-11-01 Au Optronics Corp Array substrate of a liquid crystal display and method of fabricating the same
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
NO2200606T3 (da) * 2007-09-10 2018-03-24
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
ES2526930T3 (es) 2008-05-22 2015-01-16 Astrazeneca Ab Método para el tratamiento de la hiperuricemia empleando un inhibidor de SGLT2 y composición que contiene el mismo
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CA2767258C (en) 2009-07-10 2016-09-13 Janssen Pharmaceutica Nv Crystallisation process for 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
BR112012008939B1 (pt) * 2009-10-14 2021-06-22 Janssen Pharmaceutica Nv Processo para a preparação de compostos úteis como inibidores de sglt2
MX339570B (es) 2010-05-11 2016-05-31 Janssen Pharmaceutica Nv Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
DK2697218T3 (da) 2011-04-13 2016-07-25 Janssen Pharmaceutica Nv Fremgangsmåde til fremstillingen af forbindelser anvendelige som inhibitorer af sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CA3105626A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
AU2022251165A1 (en) 2021-04-01 2023-11-09 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same

Also Published As

Publication number Publication date
CN1151405A (zh) 1997-06-11
JP3059088B2 (ja) 2000-07-04
CN1049222C (zh) 2000-02-09
TW460477B (en) 2001-10-21
CA2189603A1 (en) 1997-05-08
US5767094A (en) 1998-06-16
JPH09124686A (ja) 1997-05-13
DE69601345D1 (de) 1999-02-25
ES2128137T3 (es) 1999-05-01
EP0773226B1 (en) 1999-01-13
CA2189603C (en) 2003-06-10
KR970027098A (ko) 1997-06-24
EP0773226A1 (en) 1997-05-14
KR100333572B1 (ko) 2002-09-18
DE69601345T2 (de) 1999-06-17
ATE175676T1 (de) 1999-01-15
SG40895A1 (en) 1997-06-14
MX9605415A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
DK0773226T3 (da) Propiophenonderivater og fremgangsmåder til fremstilling deraf
HU9600834D0 (en) Quinazoline derivatives
IL148384A0 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
HK1048989A1 (en) Heterocyclic derivatives and pharmaceutical use thereof.
ATE179706T1 (de) N-heteroaryl-n'-phenylharnstoffderivate, ihre herstellung und verwendung
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
ES2163425T3 (es) Uso de raloxifeno y de sus analogos para la fabricacion de un medicamento para el tratamiento de la ateroesclerosis y la enfermedad cardiaca isquemica.
AU3636089A (en) Hydrazine derivatives for pharmaceutical use
HK1031867A1 (en) 2-phenoxyaniline derivatives
ATE114154T1 (de) Thienotriazolodiazepine und ihre pharmazeutische verwendung.
EP1034783A4 (en) AMIDE DERIVATIVES
GB9420747D0 (en) 1,5 benzodiazepine derivatives
PT855398E (pt) Derivados sasquiterpeno tendo actividade antiviral
CA2187402A1 (en) Quinoxaline Derivatives for Treating Tinnitus
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
AU7962000A (en) Us0027324for eating disorders
DK0638587T3 (da) Salmyciner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel